May 17, 2020

The Dukan Diet

The Dukan Diet
Dr Pierre Dukan
diet
weight loss
Admin
3 min
The Dukan Diet
Written by Dr Pierre Dukan To date, The Dukan Diet has been translated into nine languages and is sold in over 20 countries, including Korea, Russia, A...

Written by Dr Pierre Dukan

To date, The Dukan Diet has been translated into nine languages and is sold in over 20 countries, including Korea, Russia, America and Brazil. The Dukan Diet Recipe Book was also written, to provide not only knowledge, but also a method by which Dukan dieters could fight their weight problems. In May 2010, that launch of The Dukan Diet website, www.dukandiet.co.uk, created a higher level of personalisation which gave a whole new dimension to this diet method on an international scale.

 

For those that have not heard of it, The Dukan Diet is a high-protein, low-carb and low-fat diet which provides long-term, sustainable weight loss. It’s a simple, accessible and natural method of weight loss, which helps people reach their ideal weight.

Based on 100 natural foods, 78 protein rich foods and 28 vegetables – of which dieters may eat as much as they wish – The Dukan Diet has a unique four-phase structure; two to lose weight and two to maintain the weight.  This unique structure provides strong support for the dieter to take ownership, follow the diet and stabilise their weight long term.

Phase 1

A brief ATTACK phase with immediate results - lasting from two to seven days when you can eat as many of the 100 protein foods as you like.

Phase 2

A CRUISE phase that continues uninterrupted until the true weight is reached. Dieters alternate pure protein days with protein and vegetable days to reach their target weight with an average weight loss of 2lbs per week.

Phase 3

A CONSOLIDATION phase lasting five days for every pound lost. This phase is designed to reintroduce dieters to the ‘pleasure’ of food whilst prevent the rebound effect that occurs after any rapid form of weight loss. You can add cheese, bread, fruits, starchy food and ‘celebration’ meals.

Phase 4

A STABILISATION phase based on the following three simple principles to counter-act any mild weight gain:

  • Eat three tablespoons of oat bran per
  • day
  • Regular
  • exercise – a minimum of 20 minutes walking every
  • day
  • Have
  • a Pure Protein Attack day once a week

As well as weight loss, The Dukan Diet offers a lifetime plan geared towards a successful outcome – for dieters to reach their target weight and achieve long-term, stable weight control. This is the secret behind the diet’s success.

The Dukan Diet has been designed to appreciate that everyone is different, with different body shapes, different goals and individual tastes. There is no ‘one-diet-fits-all’, but with dukandiet.co.uk users can create a personalised plan, which works for them. Dieters are asked a number of online questions regarding their eating habits and lifestyle, as well as their physical stats, weight goals and favourite foods. Once answered, the website calculates a ‘true weight’ and prepares the personalised four-stage route towards reaching that goal. The cost of the plan is also personalised and calculated depending upon how much weight you want to lose and by when.

The Dukan Diet’s on-line forum is the strongest slimming community on the web, enabling fellow dieters to share tips and provide support for one another. This is another unique feature of The Dukan Diet, that members have access to on-line advice, support and encouragement by Dukan experts. So if, for example, a dieter has ‘broken the rules’ by eating or drinking something outside the plan, remedial action is offered without criticism or judgement.

It is these unique methods and level of detail, which have contributed to the Dukan Diet’s success today. 

About Dr Pierre Dukan

Dr Pierre Dukan is the most widely read nutritionist in France today. He is also the author of 19 books selling over 2.5 million copies. For more information on the diet, visit www.dukandiet.co.uk.

Dr Pierre Dukan

Our magazine is now available on the iPad. Click here to download it.

Share article

Apr 30, 2021

The challenges to vaccine distribution affecting everyone

covid-19vaccine
vaccinesupply
Supplychain
Blockchain
Jonathan Colehower
5 min
The challenges to vaccine distribution affecting everyone
Jonathan Colehower, CEO at CargoChain, describes the COVID-19 vaccine distribution challenges impacting every country, organisation and individual...

While it is comforting to know that vaccines against COVID-19 are showing remarkable efficacy, the world still faces intractable challenges with vaccine distribution. Specifically, the sheer number of vaccines required and the complexity of global supply chains are sure to present problems we have neither experienced nor even imagined. 

Current projections estimate that we could need 12-15 billion doses of vaccine, but the largest vaccine manufacturers produce less than half this volume in a year. To understand the scale of the problem, imagine stacking one billion pennies – you would have a stack that is 950 miles high. Now, think of that times ten. This is a massive problem that one nation can’t solve alone.  

Production capacity 

Even if we have a vaccine – can we make enough? Based on current projections, Pfizer expects to produce up to 1.3 billion doses this year. Moderna is working to expand its capacity to one billion units this year. Serum Institute of India, the world’s largest vaccine producer, is likely to produce 60% of the 3 billion doses committed by AstraZeneca, Johnson & Johnson and Sanofi. This leaves us about 7 billion doses short. 

Expanding vaccine production for most regions in the world is complicated and time-consuming. Unlike many traditional manufacturing operations that can expand relatively quickly and with limited regulation, pharmaceutical production must meet current good manufacturing practice (CGMP) guidelines. So, not only does it take time to transition from R&D to commercial manufacturing, but it could also take an additional six months to achieve CGMP certification. 

The problem becomes even more complex when considering the co-products required. Glass vials and syringes are just two of the most essential co-products needed to produce a vaccine. Last year, before COVID-19, global demand for glass vials was 12 billion. Even if it is safe to dispense ten doses per vial, there is certain to be significant pressure on world supply of the materials needed to package and distribute a vaccine.

It is imperative drug manufacturers and their raw material suppliers have clear visibility of production plans and raw material availability if there is any hope of optimizing scarce resources and maximising production yield.

Distribution requirements

It is widely known by now that temperature is a critical factor for the COVID-19 vaccine. Even the regions with the most developed logistics infrastructures and resources needed to support a cold-chain network are sure to struggle with distribution.

For the United States alone, State and local health agencies have determined distribution costs will exceed $8.4 billion, including $3 billion for workforce recruitment and training; $1.2 billion for cold-chain, $1 billion vaccination sites and $0.5 billion IT upgrades.  

The complexity of the problem increases further when considering countries such as India that do not have cold-chain logistics networks that meet vaccine requirements. Despite India’s network of 28,000 cold-chain units, none are capable of transporting vaccines below -25°Celsius. While India’s Serum Institute has licensed to manufacture AstraZeneca’s vaccine, which can reportedly be stored in standard refrigerated environments, even a regular vaccine cold chain poses major challenges.

Furthermore, security will undoubtedly become a significant concern that global authorities must address with a coordinated solution. According to the Pharmaceutical Security Institute, theft and counterfeiting of pharmaceutical products rose nearly 70% over the past five years. As with any valuable and scarce product, counterfeits will emerge. Suppliers and producers are actively working on innovative approaches to limit black-market interference. Corning, for example, is equipping vials with black-light verification to curb counterfeiting.

Clearly, this is a global problem that will require an unprecedented level of collaboration and coordination.

Disconnected information systems 

While it is unreasonable to expect every country around the world will suddenly adopt a standard technology that would provide immediate, accurate and available information for everyone, it is not unreasonable to think that we can align on a standard taxonomy that can serve as a Rosetta Stone for collaboration. 

A shared view of the situation (inventory, raw materials, delivery, defects) will provide every nation with the necessary information to make life-saving decisions, such as resource pooling, stock allocations and population coverage.

By allowing one central authority, such as the World Health Organization, to organize and align global leaders to a single collaboration standard, such as GS1, and a standard sharing protocol, such as DSCSA, then every supply chain participant will have the ability to predict, plan and execute in a way that maximises global health.

Political influence and social equality 

As if we don’t have enough stress and churn in today’s geopolitical environment, we must now include the challenge of “vaccine nationalism.” While this might not appear to be a supply chain problem, per se, it is a critical challenge that will hinge on supply chain capabilities.

In response to the critical supply issues the world experienced with SARS-CoV-2, the World Health Organization, Gavi, the Vaccine Alliance and the Coalition for Epidemic Preparedness Innovations (CEPI) formed Covax: a coalition dedicated to equitable distribution of 2 billion doses of approved vaccines to its 172 member countries. Covax is currently facilitating a purchasing pool and has made commitments to buy massive quantities of approved vaccines when they become available.  

However, several political powerhouse countries, such as the United States and Russia, are not participating. Instead, they are striking bilateral deals with drug manufacturers – essentially, competing with the rest of the world to secure a national supply. Allocating scarce resources is never easy, but when availability could mean the difference between life and death, it becomes almost impossible.

Global production, distribution and social equality present dependent yet conflicting realities that will demand global supply chains provide complete transparency and an immutable chain of custody imperative to vaccine distribution. 

The technology is available today – we just need to use it. We have the ability to track every batch, pallet, box, vile and dose along the supply chain. We have the ability to know with absolute certainty that the vaccine is approved, where and when it was manufactured, how it was handled and whether it was compromised at any point in the supply chain. Modern blockchain technologies should be applied so that every nation, institution, regulator, doctor and patient can have confidence in knowing that they are making an impact in eradicating COVID-19.

Share article